UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER
THE
SECURITIES EXCHANGE ACT OF 1934
For
the month of October 2025
Commission
File Number: 001-41115
GENENTA
SCIENCE S.P.A.
(Translation
of registrant’s name into English)
Via
Olgettina No. 58
20132
Milan, Italy
(Address
of Principal Executive Offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
This
report on Form 6-K is incorporated by reference into the registrant’s registration statement on Form F-3 (File No. 333-271901).
Other
Events
On September 30, 2025, Carlo
Russo, MD, notified Genenta Science S.p.A. (the “Company”) of his resignation as Chief Medical Officer and
Head of Development. Any required notice periods relating to his resignation as provided for in Dr. Russo’s employment agreement
with the Company was waived by the Company, and the resignation was effective immediately. The resignation of Dr. Russo was for personal
reasons and does not result from a disagreement with the Company.
Appointment
of Dr. Francesco Galimi as acting Chief Medical Officer and Head of Development
On
September 30, 2025, Dr. Francesco Galimi has been appointed to serve as the acting Chief Medical Officer and Head of Development,
effective immediately.
Dr.
Galimi, age 58, has been serving on the Board of Directors of Genenta Science SpA since April 2025. Dr. Galimi is a physician-executive
with over 30 years of experience in healthcare R&D, including leadership roles in private and public biotechs as well as large pharma
companies. Most recently, he was Senior Vice President and Chief Medical Officer at Adicet Bio, a company focused on allogeneic cell
therapy technologies in hemato-oncology and autoimmune disorders. Previously, he served as Global Program General Manager at Amgen, where
he led a portfolio of oncology programs, from pre-IND to late-stage. Prior to Amgen, Dr. Galimi was Head of Clinical Development at Onyx
Pharmaceuticals and Executive Medical Leader at GNF/Novartis. Dr. Galimi holds an M.D. from the University of Torino Medical School with
a specialty certification in Medical Oncology, and a Ph.D. in Oncology from the University of Torino Medical School. He conducted his
post-doctoral research, focused on gene transfer models in hematology, at the Salk Institute in La Jolla, California.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
GENENTA SCIENCE S.P.A. |
| |
|
| |
By: |
/s/
Richard B. Slansky |
| |
Name: |
Richard B. Slansky |
| |
Title: |
Chief Financial Officer |
Dated:
October 3, 2025
